Comparing Effect and Change Processes in Cognitive Behavioral Therapy and Emotion-Focused Therapy for Depression
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04690946 |
|
Recruitment Status :
Recruiting
First Posted : December 31, 2020
Last Update Posted : February 2, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Depression | Behavioral: Cognitive Behavioral Therapy Behavioral: Emotion-Focused Therapy | Not Applicable |
Depression is a widespread mental disorder which can result in severe impairment and reduced quality of life for those affected. Cognitive behavioral therapy (CBT) is the approach with strongest empirical support, and is often recommended as treatment for depression, as in the NICE Guidelines for Depression from 2009. However, research indicates that not all patients respond to CBT, indicating a need to expand the range of available evidence-based psychotherapies, and mapping the mechanisms of change in existing treatments.
Emotion focused therapy (EFT) is one promising treatment for depression with empirical support for its efficacy. A previous study found equal outcome in CBT and Process-Experiential treatment/EFT for depression, but more studies are needed to replicate these findings across cultural contexts. The main aim of this study is to investigate whether there are significant differences in the therapeutic effect of EFT compared to that of CBT for patients with moderate and major depressive disorder in a Norwegian outpatient setting.
Although several psychotherapeutic approaches have shown efficacy in the treatment of depression, no psychotherapeutic interventions is beneficial for all patients. There is a need for research that investigates what treatments works for whom, based on patient characteristics and preferences. The present study will investigate whether patient characteristics moderate treatment outcome, both within and between treatment conditions. In addition, qualitative interviews will be conducted to get a deeper understanding of what clients find helpful and challenging within the CBT and EFT condition, and to explore the experience of patients who drop-out of the treatment process.
In order to further develop psychotherapeutic treatments and increase their effectiveness, there is a need to identify processes that are related to good and poor outcome. Process-outcome studies are commonly used for this purpose. The present study will investigate and compare characteristics of psychotherapy processes in both the CBT and EFT conditions and how these are related to outcome.
Study design and Method
The study will be conducted as a randomized controlled trial (RCT) in order to compare the efficacy of EFT to CBT. RCT's are considered the gold standard for efficacy studies. Participants will be recruited from the Norwegian mental health program "Return to work", a publicly funded treatment program where patients with common mental health issues receives outpatient psychotherapeutic treatment to reduce and prevent sick leave.
The present study will address the following research hypothesis and questions:
- EFT and CBT will not result in significantly different outcome in the treatment of patients with moderate and major depressive disorder.
- Patient characteristics (severity of depression, adverse childhood experiences and clients' initial ability to make sense of their experience) will moderate treatment outcome for both conditions.
- Will therapeutic processes (therapeutic alliance, therapist empathy, clients' ability to make sense of their experience and emotional processing) mediate treatment outcome equally for both conditions?
- What do patients in both conditions describe as helpful and unhelpful aspects of treatment?
- How do patients in both conditions describe their own change or lack or change after treatment?
- How do patients that choose to drop out of treatment describe the processes leading to that decision?
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 120 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Randomized Clinical Trial |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Randomized Controlled Study Comparing the Therapeutic Effect and Change Processes in Cognitive Behavioral Therapy and Emotion-Focused Therapy for Depression |
| Actual Study Start Date : | January 20, 2021 |
| Estimated Primary Completion Date : | December 30, 2022 |
| Estimated Study Completion Date : | December 30, 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Cognitive Behavioral Therapy
14-18 sessions of psychotherapy according to principles of Cognitive Behavioral Therapy
|
Behavioral: Cognitive Behavioral Therapy
14-18 sessions of CBT
Other Name: CBT |
|
Active Comparator: Emotion-Focused Therapy
14-18 sessions of psychotherapy according to principles of Emotion Focused Therapy
|
Behavioral: Emotion-Focused Therapy
14-18 sessions of EFT
Other Name: EFT |
- Change in Beck Depression Inventory from session to session [ Time Frame: 1 week before treatment startup, 1 day after each therapy session, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up ]Self-report measure of depressive symptoms, ranging from minimum 0 and maximum 63. Higher scores suggests worse outcome.
- Change in Beck Anxiety Inventory [ Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up ]Self-report measure of anxiety symptoms, ranging from minimum 0 and maximum 63. Higher scores suggests worse outcome.
- Change in Repetitive Eating Questionnaire [ Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up ]Self-report measure of symptoms related to eating disorders, average scores, minimum 0, maximum 6, higher score indicates worse outcome.
- Change in Inventory of Interpersonal problems [ Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up ]Self-report measure of interpersonal difficulties, average scores minimum 0, maximum 4. Higher score suggests worse outcome.
- Change in The Acceptance and Action Questionnaire from session to session [ Time Frame: 1 week before treatment startup, 1 day after each therapy session, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up ]Self-report measure of psychological flexibility, average scores minimum 1, maximum 7. Higher score suggests worse outcome.
- Change in Emotion Approach Coping Scale [ Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up ]Self-report measure of emotional processing ability, average scores minimum 1, maximum 4. Higher score suggests better outcome.
- Change in Penn State Worry Questionaire [ Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up ]Self-report measure of rumination and cognitive processing, total scores minimum 16, maximum 80. Higher score suggests worse outcome.
- Change in Self-Compassion Scale [ Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up ]Self-report measure of self-relating, average scores, minimum 1, maximum 5, higher scores suggests better outcome.
- Change in Quality of life questionnaire [ Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up ]Self-report measure of quality of life, average scores, minimum 1, maximum 5, higher scores indicate better outcome.
- Change in Working Alliance Inventory - short version [ Time Frame: 1 day after 1st through 14th therapy session. ]Self report measure on experience of therapeutic alliance, average scores, minimum 1, maximum 7, higher scores suggests better outcome.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Moderate or major depressive episode as primary diagnosis
Exclusion Criteria:
- Serious mental illness (schizophrenia, severe bipolar disorder, recent or current psychotic episode) or intellectual disability.
- Severe alcohol or drug abuse, last 12 months.
- Suicidality last 6 months
- Severe medical issues
- If the participant is on antidepressive medication, the dosage must have been stable for more than 4 weeks, and the participant must consent to staying on the same dosage for the duration of the treatment.
- The participant is currently in another treatment for depression
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04690946
| Contact: Jan R Stiegler, PhD | +4792211019 | stiegler@ipr.no | |
| Contact: Hanna Aardal, Cand Psychol | +4795287217 | aardal@ipr.no |
| Norway | |
| Institutt for Psykologisk rådgivning | Recruiting |
| Bergen, Norway, 5012 | |
| Contact: Jan R Stiegler, PhD +4792211019 stiegler@ipr.no | |
| Contact: Hanna Aardal, Cand Psychol +4795287217 aardal@ipr.no | |
| Principal Investigator: | Jan Reidar Stiegler, PhD | Institute for Psychological Counselling |
| Responsible Party: | Institutt for Psykologisk Radgivning |
| ClinicalTrials.gov Identifier: | NCT04690946 |
| Other Study ID Numbers: |
IPR |
| First Posted: | December 31, 2020 Key Record Dates |
| Last Update Posted: | February 2, 2021 |
| Last Verified: | January 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Depression Depressive Disorder Behavioral Symptoms Mood Disorders Mental Disorders |

